Literature DB >> 21315402

Genetic bases of the temperature-sensitive phenotype of a master donor virus used in live attenuated influenza vaccines: A/Leningrad/134/17/57 (H2N2).

Irina Isakova-Sivak1, Li-Mei Chen, Yumiko Matsuoka, J Theo M Voeten, Irina Kiseleva, Jacco G M Heldens, Han van den Bosch, Alexander Klimov, Larisa Rudenko, Nancy J Cox, Ruben O Donis.   

Abstract

Trivalent live attenuated influenza vaccines whose type A components are based on cold-adapted A/Leningrad/134/17/57 (H2N2) (caLen17) master donor virus (MDV) have been successfully used in Russia for decades to control influenza. The vaccine virus comprises hemagglutinin and neuraminidase genes from the circulating viruses and the remaining six genes from the MDV. The latter confer temperature-sensitive (ts) and attenuated (att) phenotypes. The ts phenotype of the vaccine virus is a critical biological determinant of attenuation of virulence. We developed a plasmid-based reverse genetics system for MDV caLen17 to study the genetic basis of its ts phenotype. Mutations in the polymerase proteins PB1 and PB2 played a crucial role in the ts phenotype of MDV caLen17. In addition, we show that caLen17-specific ts mutations could impart the ts phenotype to the divergent PR8 virus, suggesting the feasibility of transferring the ts phenotype to new viruses of interest for vaccine development. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21315402     DOI: 10.1016/j.virol.2011.01.004

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  37 in total

1.  Safety, immunogenicity and protection of A(H3N2) live attenuated influenza vaccines containing wild-type nucleoprotein in a ferret model.

Authors:  Daniil A Korenkov; Karen L Laurie; Patrick C Reading; Louise A Carolan; Kok Fei Chan; Irina I Isakova-Sivak; Tatiana A Smolonogina; Kanta Subbarao; Ian G Barr; Julie Villanueva; Svetlana Shcherbik; Tatiana Bousse; Larisa G Rudenko
Journal:  Infect Genet Evol       Date:  2018-06-19       Impact factor: 3.342

2.  The temperature-sensitive and attenuation phenotypes conferred by mutations in the influenza virus PB2, PB1, and NP genes are influenced by the species of origin of the PB2 gene in reassortant viruses derived from influenza A/California/07/2009 and A/WSN/33 viruses.

Authors:  Andrew J Broadbent; Celia P Santos; Rachel A Godbout; Kanta Subbarao
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

3.  Comparative studies of infectivity, immunogenicity and cross-protective efficacy of live attenuated influenza vaccines containing nucleoprotein from cold-adapted or wild-type influenza virus in a mouse model.

Authors:  Irina Isakova-Sivak; Daniil Korenkov; Tatiana Smolonogina; Tatiana Tretiak; Svetlana Donina; Andrey Rekstin; Anatoly Naykhin; Svetlana Shcherbik; Nicholas Pearce; Li-Mei Chen; Tatiana Bousse; Larisa Rudenko
Journal:  Virology       Date:  2016-11-06       Impact factor: 3.616

4.  A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial.

Authors:  Raffael Nachbagauer; Jodi Feser; Abdollah Naficy; David I Bernstein; Jeffrey Guptill; Emmanuel B Walter; Franceso Berlanda-Scorza; Daniel Stadlbauer; Patrick C Wilson; Teresa Aydillo; Mohammad Amin Behzadi; Disha Bhavsar; Carly Bliss; Christina Capuano; Juan Manuel Carreño; Veronika Chromikova; Carine Claeys; Lynda Coughlan; Alec W Freyn; Christopher Gast; Andres Javier; Kaijun Jiang; Chiara Mariottini; Meagan McMahon; Monica McNeal; Alicia Solórzano; Shirin Strohmeier; Weina Sun; Marie Van der Wielen; Bruce L Innis; Adolfo García-Sastre; Peter Palese; Florian Krammer
Journal:  Nat Med       Date:  2020-12-07       Impact factor: 53.440

5.  Live Attenuated Influenza Vaccines engineered to express the nucleoprotein of a recent isolate stimulate human influenza CD8+ T cells more relevant to current infections.

Authors:  D Korenkov; T H O Nguyen; I Isakova-Sivak; T Smolonogina; L E Brown; K Kedzierska; L Rudenko
Journal:  Hum Vaccin Immunother       Date:  2018-01-23       Impact factor: 3.452

6.  Live attenuated influenza vaccine viral vector induces functional cytotoxic T-cell immune response against foreign CD8+ T-cell epitopes inserted into NA and NS1 genes using the 2A self-cleavage site.

Authors:  Tatiana Kotomina; Daniil Korenkov; Victoria Matyushenko; Polina Prokopenko; Larisa Rudenko; Irina Isakova-Sivak
Journal:  Hum Vaccin Immunother       Date:  2018-08-29       Impact factor: 3.452

7.  H5N2 vaccine viruses on Russian and US live attenuated influenza virus backbones demonstrate similar infectivity, immunogenicity and protection in ferrets.

Authors:  Rita Czakó; Leatrice Vogel; Troy Sutton; Yumiko Matsuoka; Florian Krammer; Zhongying Chen; Hong Jin; Kanta Subbarao
Journal:  Vaccine       Date:  2018-03-01       Impact factor: 3.641

8.  Restricted replication of the live attenuated influenza A virus vaccine during infection of primary differentiated human nasal epithelial cells.

Authors:  William A Fischer; Landon S King; Andrew P Lane; Andrew Pekosz
Journal:  Vaccine       Date:  2015-07-18       Impact factor: 3.641

9.  Development of an RNA Strand-Specific Hybridization Assay To Differentiate Replicating versus Nonreplicating Influenza A Viruses.

Authors:  Genyan Yang; Erin N Hodges; Jörn Winter; Natosha Zanders; Svetlana Shcherbik; Tatiana Bousse; Janna R Murray; A K M Muraduzzaman; Mahbubur Rahman; A S M Alamgir; Meerjady Sabrina Flora; Lenee Blanton; John R Barnes; David E Wentworth; C Todd Davis
Journal:  J Clin Microbiol       Date:  2020-05-26       Impact factor: 5.948

10.  Characterization of reverse genetics-derived cold-adapted master donor virus A/Leningrad/134/17/57 (H2N2) and reassortants with H5N1 surface genes in a mouse model.

Authors:  Irina Isakova-Sivak; Li-Mei Chen; Melissa Bourgeois; Yumiko Matsuoka; J Theo M Voeten; Jacco G M Heldens; Han van den Bosch; Alexander Klimov; Larisa Rudenko; Nancy J Cox; Ruben O Donis
Journal:  Clin Vaccine Immunol       Date:  2014-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.